

Copy of MD7512 Clinical Presentation & Management of Diabetes: Complications & Cardiovascular Disease

View Online



Clinical Presentation & Management of Diabetes:
Complications & Cardiovascular Disease

1

Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

2

Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

3

International Textbook of Diabetes Mellitus. 4th ed. John Wiley & Sons, Incorporated 2015.
<http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=1895437>

4

Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE.
<https://www.nice.org.uk/guidance/ng17>

5

Type 2 diabetes in adults: management | Guidance and guidelines | NICE.
<https://www.nice.org.uk/guidance/ng28>

6

Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The Lancet Published Online First: February 2017. doi:10.1016/S0140-6736(17)30058-2

7

Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet 2014;**383**:69-82. doi:10.1016/S0140-6736(13)60591-7

8

Matheus AS de M, Tannus LRM, Cobas RA, et al. Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension 2013;**2013**:1-15. doi:10.1155/2013/653789

9

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858717300335>

10

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947>

11

Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 2008;**359**:1577-89. doi:10.1056/NEJMoa0806470

12

Effect of intensive blood-glucose control with metformin on complications in overweight

patients with type 2 diabetes (UKPDS 34). *The Lancet* 1998;**352**:854–65.
doi:10.1016/S0140-6736(98)07037-8

13

Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New England Journal of Medicine* 2008;**358**:2545–59. doi:10.1056/NEJMoa0802743

14

Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia* 2009;**52**:2288–98.
doi:10.1007/s00125-009-1470-0

15

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. *New England Journal of Medicine* 2011;**364**:818–28. doi:10.1056/NEJMoa1006524

16

Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *BMJ* 2010;**340**:b5444–b5444. doi:10.1136/bmj.b5444

17

Duckworth W, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. *New England Journal of Medicine* 2009;**360**:129–39.
doi:10.1056/NEJMoa0808431

18

Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 2015;**372**:2197–206. doi:10.1056/NEJMoa1414266

19

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine* 2008;**358**:2560–72. doi:10.1056/NEJMoa0802987

20

Wong MG, Perkovic V, Chalmers J, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care* 2016;**39**:694–700. doi:10.2337/dc15-2322

21

Giorgino F, Home PD, Tuomilehto J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? *Diabetes Care* 2016;**39**:S187–95. doi:10.2337/dcS15-3023

22

Gæde P, Lund-Andersen H, Parving H-H, et al. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. *New England Journal of Medicine* 2008;**358**:580–91. doi:10.1056/NEJMoa0706245

23

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *New England Journal of Medicine* 1993;**329**:977–86. doi:10.1056/NEJM199309303291401

24

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. *New England Journal of Medicine* 2005;**353**:2643–53. doi:10.1056/NEJMoa052187

25

Orchard TJ, Nathan DM, Zinman B, et al. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. *JAMA* 2015;**313**.

doi:10.1001/jama.2014.16107

26

Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. *Diabetologia* 2016;**59**:2298–307.
doi:10.1007/s00125-016-4065-6

27

Bianchi C, Miccoli R, Del Prato S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports* 2013;**13**:403–10. doi:10.1007/s11892-013-0371-2

28

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine* 2015;**373**:2117–28.
doi:10.1056/NEJMoa1504720

29

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 2016;**375**:311–22.
doi:10.1056/NEJMoa1603827

30

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ* 2011;**343**:d4169–d4169. doi:10.1136/bmj.d4169

31

Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *The Lancet* 2009;**373**:1765–72.
doi:10.1016/S0140-6736(09)60697-8

32

Sultan A, Perriard F, Macioce V, et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. *Diabetic Medicine* Published Online First: 18 April 2017. doi:10.1111/dme.13364

33

Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine* 2017;**376**:1407–18. doi:10.1056/NEJMoa1608664

34

Sultan A, Perriard F, Macioce V, et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. *Diabetic Medicine* Published Online First: 18 April 2017. doi:10.1111/dme.13364

35

Soliman EZ, Backlund J-YC, Bebu I, et al. Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. *Diabetes Care* 2017;**40**:793–9. doi:10.2337/dc16-2050

36

Solomon SD, Chew E, Duh EJ, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;**40**:412–418. *Diabetes Care* 2017;**40**:809.3-809. doi:10.2337/dc17-er06e

37

Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. *New England Journal of Medicine* 2017;**376**:1419–29. doi:10.1056/NEJMoa1610187

38

Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine* 2017;**376**:1407–18. doi:10.1056/NEJMoa1608664

39

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine* 2017;**377**:300–1. doi:10.1056/NEJMc1706292

40

Older antidiabetic drugs | *The British Journal of Cardiology*.
<https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/>

41

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- *ClinicalKey*.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>

42

Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 2017;**377**:1228–39. doi:10.1056/NEJMoa1612917

43

Pickering RJ, Rosado CJ, Sharma A, et al. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. *Clinical & Translational Immunology* 2018;**7**. doi:10.1002/cti2.1016

44

Microvascular Complications and Foot Care. *Diabetes Care* 2017;**40**:S88–98.
doi:10.2337/dc17-S013

45

Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. *BMJ* Published Online First: 17 January 2017.
doi:10.1136/bmj.i6505

46

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *The Lancet* 2010;**375**:2215–22.
doi:10.1016/S0140-6736(10)60484-9

47

The changing face of diabetes complications - ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109>

48

Wong MG, Perkovic V, Chalmers J, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care* 2016;**39**:694–700.
doi:10.2337/dc15-2322

49

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. *New England Journal of Medicine* 2011;**364**:829–41. doi:10.1056/NEJMoa1008862

50

Wannamethee SG, Shaper AG, Whincup PH, et al. Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel risk factors. *Archives of Internal Medicine* 2011;**171**.
doi:10.1001/archinternmed.2011.2

51

Yudkin JS, Richter B, Gale EA. Intensified glucose control in type 2 diabetes—whose agenda? *The Lancet* 2011;**377**:1220–2. doi:10.1016/S0140-6736(10)61112-9

52

Zhang C-Y, Sun A-J, Zhang S-N, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. *Annals of Medicine* 2010;**42**:305–15. doi:10.3109/07853891003796752

53

Ele Ferrannini. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. *European Heart Journal* 2015;**36**:2288–96. <http://eurheartj.oxfordjournals.org/content/36/34/2288>

54

Fox CS, Golden SH, Anderson C, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. *Diabetes Care* 2015;**38**:1777–803. doi:10.2337/dci15-0012

55

Bianchi C, Miccoli R, Del Prato S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports* 2013;**13**:403–10. doi:10.1007/s11892-013-0371-2

56

Khunti K, Davies M, Majeed A, et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care* 2015;**38**:316–22. doi:10.2337/dc14-0920

57

Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 2015;**372**:2197–206. doi:10.1056/NEJMoa1414266

58

Cefalu WT, Rosenstock J, LeRoith D, et al. Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". *Diabetes Care* 2016;**39**:664–7. doi:10.2337/dc16-0405

59

Black JA, Sharp SJ, Wareham NJ, et al. Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. *British Journal of General Practice* 2014;**64**:e208–16. doi:10.3399/bjgp14X677833

60

Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia* 2009;**52**:2288–98. doi:10.1007/s00125-009-1470-0

61

Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *The Lancet Diabetes & Endocrinology* 2017;**5**:431–7. doi:10.1016/S2213-8587(17)30104-3

62

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>

63

Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with

type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. *International Journal of Cardiology* 2010;**141**:157–66.
doi:10.1016/j.ijcard.2008.11.211

64

Richard W. Nesto. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? *Clinical Diabetes* 2008;**26**
.http://go.galegroup.com/ps/i.do?id=GALE|A174972167&v=2.1&u=leicester&it=r&p=EAIM
&sw=w&asid=07d8e79bb8f42665bb52cc5732948c88

65

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. *New England Journal of Medicine* 2010;**362**:1563–74. doi:10.1056/NEJMoa1001282

66

Filippatos T, Tsimihodimos V, Pappa E, et al. Pathophysiology of diabetic dyslipidaemia. *Current Vascular Pharmacology* 2017;**15**:1–1.

67

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Atherosclerosis* 2016;**252**:207–74.
doi:10.1016/j.atherosclerosis.2016.05.037

68

White J, Swerdlow DI, Preiss D, et al. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. *JAMA Cardiology* 2016;**1**. doi:10.1001/jamacardio.2016.1884

69

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey.
https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036

70

Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011. <http://www.nice.org.uk/guidance/cg127>

71

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine 2010;**362**:1575–85. doi:10.1056/NEJMoa1001286

72

Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. The Lancet 2012;**380**:601–10. doi:10.1016/S0140-6736(12)60987-8

73

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ : British Medical Journal 1998;**317**.<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28659/>

74

Whelton PK. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. Archives of Internal Medicine 2005;**165**. doi:10.1001/archinte.165.12.1401

75

Barzilay JI, Davis BR, Pressel SL, et al. Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. Circulation: Cardiovascular Quality and Outcomes 2012;**5**:153–62. doi:10.1161/CIRCOUTCOMES.111.962522

76

Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients

with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *The Lancet* 2002;**359**:1004–10. doi:10.1016/S0140-6736(02)08090-X

77

Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *The Lancet* 2005;**366**:895–906. doi:10.1016/S0140-6736(05)67185-1

78

Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. *Journal of the American College of Cardiology* 2010;**56**:77–85. doi:10.1016/j.jacc.2010.02.046

79

Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *The Lancet* 2007;**369**:201–7. doi:10.1016/S0140-6736(07)60108-1

80

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *New England Journal of Medicine* 2010;**362**:1575–85. doi:10.1056/NEJMoa1001286

81

Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. *Diabetologia* 1996;**39**:1646–54. doi:10.1007/s001250050629

82

Bangalore S, Kumar S, Lobach I, et al. Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. *Circulation* 2011;**123**:2799–810.

doi:10.1161/CIRCULATIONAHA.110.016337

83

Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. Archives of Internal Medicine 2005;**165**. doi:10.1001/archinte.165.12.1410

84

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey.
<https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020>

85

Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998>

86

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020>

87

Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;**40**:412-8. doi:10.2337/dc16-2641

88

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet 2010;**376**:124-36. doi:10.1016/S0140-6736(09)62124-3

89

Adamsson Eryd S, Svensson A-M, Franzén S, et al. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. *Diabetic Medicine* 2017;**34**:411–8. doi:10.1111/dme.13266

90

Liew G, Mitchell P, Wong TY. Systemic management of diabetic retinopathy. *BMJ* 2009;**338**:b441–b441. doi:10.1136/bmj.b441

91

Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology* Published Online First: 7 March 2017. doi:10.1136/bjophthalmol-2016-310063

92

Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology* Published Online First: 7 March 2017. doi:10.1136/bjophthalmol-2016-310063

93

Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology* Published Online First: 7 March 2017. doi:10.1136/bjophthalmol-2016-310063

94

Solomon SD, Chew E, Duh EJ, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;**40**:412–418. *Diabetes Care* Published Online First: 21 April 2017. doi:10.2337/dc17-er06e

95

Solomon SD, Chew E, Duh EJ, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care* Published Online First: 21 April 2017. doi:10.2337/dc17-er06e

96

Rosenberg JB, Tsui I. Screening for Diabetic Retinopathy. *New England Journal of Medicine* 2017;**376**:1587–8. doi:10.1056/NEJMe1701820

97

Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. *New England Journal of Medicine* 2017;**376**:1507–16. doi:10.1056/NEJMoa1612836

98

Moreton RBR, Stratton IM, Chave SJ, et al. Factors determining uptake of diabetic retinopathy screening in Oxfordshire. *Diabetic Medicine* 2017;**34**:993–9. doi:10.1111/dme.13350

99

Melanie Davies. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. *Clinical Pharmacology : Advances and Applications* 2016;**8**. doi:doi: 10.2147/CPAA.S82008

100

Navaneethan SD, Schold JD, Jolly SE, et al. Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. *American Journal of Kidney Diseases* Published Online First: February 2017. doi:10.1053/j.ajkd.2016.11.018

101

Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey.
<https://www.clinicalkey.com/#!/content/journal/1-s2.0-S1262363617300022>

102

Webb DR, Zaccardi F, Davies MJ, et al. Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. *Diabetes/Metabolism Research and Reviews* Published Online First: 2016. doi:10.1002/dmrr.2877

103

Çakici N, Fakkal TM, van Neck JW, et al. Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine* 2016;**33**:1466–76. doi:10.1111/dme.13083

104

Koye DN, Shaw JE, Reid CM, et al. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. *Diabetic Medicine* Published Online First: February 2017. doi:10.1111/dme.13324

105

Johal S, Jackson-Spence F, Gillott H, et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. *Diabetic Medicine* Published Online First: 5 June 2017. doi:10.1111/dme.13383

106

Clokier M, Greenway AL, Harding K, et al. New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium. *Diabetic Medicine* 2017;**34**:305–15. doi:10.1111/dme.13313

107

Game F. Classification of diabetic foot ulcers. *Diabetes/Metabolism Research and Reviews* 2016;**32**:186–94. doi:10.1002/dmrr.2746

108

Jhamb S, Vangaveti VN, Malabu UH. Genetic and molecular basis of diabetic foot ulcers: Clinical review. *Journal of Tissue Viability* 2016;**25**:229–36. doi:10.1016/j.jtv.2016.06.005

109

Boulton AJ, Jeffcoate WJ, Jones TL, et al. International collaborative research on Charcot's disease - 2009. *The Lancet* 2009;**373**:105–6. doi:10.1016/S0140-6736(09)60019-2

110

Yavuz M, Ersen A, Hartos J, et al. Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration. *Diabetes Care* 2017;**40**:e14–5. doi:10.2337/dc16-2204

111

P Naidoo. Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team. *The British Journal of Radiology* 2015;**88**. doi:doi: 10.1259/bjr.20150135

112

Diabetic foot problems: prevention and management | Guidance and guidelines | NICE. <https://www.nice.org.uk/guidance/ng19>

113

Holt RIG. Understanding of the causes and management of diabetic foot disease. *Diabetic Medicine* 2017;**34**:303–4. doi:10.1111/dme.13319

114

Jin D, Xu Y, Geng D, et al. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. *Diabetes Research and Clinical Practice* 2010;**89**:10–5. doi:10.1016/j.diabres.2010.03.021

115

Çakici N, Fakkal TM, van Neck JW, et al. Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine* 2016;**33**:1466–76. doi:10.1111/dme.13083

116

Foresta C, Ferlin A, Lenzi A, et al. The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention. *Andrology* Published Online First: March 2017. doi:10.1111/andr.12342

117

Azmi S, Ferdousi M, Alam U, et al. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. *Diabetologia* Published Online First: 29 March 2017. doi:10.1007/s00125-017-4245-z

118

Andersson DP, Trolle Lagerros Y, Grotta A, et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. *Heart* Published Online First: 9 March 2017. doi:10.1136/heartjnl-2016-310746

119

Omland T, Randby A, Hrubos-Strøm H, et al. Relation of Erectile Dysfunction to Subclinical Myocardial Injury. *The American Journal of Cardiology* 2016;**118**:1821–5. doi:10.1016/j.amjcard.2016.08.070

120

Braffett BH, Wessells H, Sarma AV. Urogenital Autonomic Dysfunction in Diabetes. *Current Diabetes Reports* 2016;**16**. doi:10.1007/s11892-016-0824-5

121

Hotaling JM, Sarma AV, Patel DP, et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. *Diabetes Care* 2016;**39**:1587–93. doi:10.2337/dc16-0059

122

Giovanni Corona. Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. PLoS ONE 2016;**11**. doi:doi:10.1371/journal.pone.0157915

123

Santi D, Granata ARM, Guidi A, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. European Journal of Endocrinology 2016;**174**:513–22. doi:10.1530/EJE-15-1100

124

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>

125

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>

126

Malavige LS, Wijesekara P, Ranasinghe P, et al. The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. European Journal of Medical Research 2015; **20**. doi:10.1186/s40001-015-0186-5

127

Hotaling JM, Sarma AV, Patel DP, et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care 2016;**39**:1587–93. doi:10.2337/dc16-0059

128

Dhatariya KK, Vellanki P. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). *Current Diabetes Reports* 2017;**17**. doi:10.1007/s11892-017-0857-4

129

Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. *Prime*
https://www.unboundmedicine.com/medline/citation/22586788/Assessing_the_relationship_between_admission_glucose_levels_subsequent_length_of_hospital_stay_readmission_and_mortality_

130

Dhatariya K, Levy N, Kilvert A, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. *Diabetic Medicine* 2012;**29**:420–33. doi:10.1111/j.1464-5491.2012.03582.x

131

The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - *ClinicalKey*.
<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728>

132

Scott AR. Management of hyperosmolar hyperglycaemic state in adults with diabetes. *Diabetic Medicine* 2015;**32**:714–24. doi:10.1111/dme.12757

133

Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, . Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. *Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges*
<http://www.sciencedirect.com.ezproxy4.lib.le.ac.uk/science/article/pii/S0149291816307792>

134

Chloe L. Edridge. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE 2015;**10**. doi:doi: 10.1371/journal.pone.0126427

135

Khunti K, Davies M, Majeed A, et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care 2015;**38**:316–22. doi:10.2337/dc14-0920

136

Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care 2015;**38**:1583–91. doi:10.2337/dc15-0279

137

Zaccardi F, Webb DR, Davies MJ, et al. Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. Diabetologia Published Online First: 17 March 2017. doi:10.1007/s00125-017-4235-1

138

Zaccardi F, Webb DR, Davies MJ, et al. Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England. Diabetes, Obesity and Metabolism Published Online First: April 2017. doi:10.1111/dom.12941

139

Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology 2016;**12**:222–32. doi:10.1038/nrendo.2016.15

140

Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology 2016;**12**:222–32.

doi:10.1038/nrendo.2016.15

141

Micha R, Peñalvo JL, Cudhea F, et al. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. *JAMA* 2017;**317**. doi:10.1001/jama.2017.0947

142

Khunti K, Wolden ML, Thorsted BL, et al. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. *Diabetes Care* 2013;**36**:3411–7. doi:10.2337/dc13-0331

143

Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovascular Diabetology* 2015; **14**. doi:10.1186/s12933-015-0260-x

144

Nicolucci A, Standl E. Antiplatelet Therapy for Every Diabetic Person? *Diabetes Care* 2011; **34**:S150–4. doi:10.2337/dc11-s210

145

Seidu S, Achana FA, Gray LJ, et al. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. *Diabetic Medicine* 2016;**33**:280–9. doi:10.1111/dme.12885

146

The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check.
http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/

147

Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. *Diabetic Medicine* 2017;**34**:316–27. doi:10.1111/dme.13133

148

Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabetic Medicine* 2014;**31**:764–72. doi:10.1111/dme.12428

149

Dana Dabelea. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. *JAMA*;**317**:825–35. doi:10.1001/jama.2017.0686

150

Personalised treatment targets in type 2 diabetes patients: The Dutch approach - ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626>

151

Dwamena F, Holmes-Rovner M, Gaulden CM, et al. Interventions for providers to promote a patient-centred approach in clinical consultations. In: *Cochrane Database of Systematic Reviews*. Chichester, UK: : John Wiley & Sons, Ltd 1996.
doi:10.1002/14651858.CD003267.pub2

152

Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862>

153

Denig P, Schuling J, Haaijer-Ruskamp F, et al. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. *BMJ* 2014; **349**:g5651–g5651. doi:10.1136/bmj.g5651

154

Abdul-Ghani M, DeFronzo RA, Del Prato S, et al. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? *Diabetes Care* 2017;**40**:813–20. doi:10.2337/dc16-2736

155

Kaul S. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. *Diabetes Care* 2017;**40**:821–31. doi:10.2337/dc17-0291

156

Ritholz MD, MacNeil T, Weinger K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine* Published Online First: 13 July 2017. doi:10.1111/dme.13419

157

Ritholz MD, MacNeil T, Weinger K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine* 2017;**34**:1447–55. doi:10.1111/dme.13419

158

Holt RIG, Cockram CS, Flyvbjerg A, et al., editors. *Textbook of diabetes*. Fifth edition. Chichester, West Sussex, UK: : Wiley Blackwell 2017.
<http://ezproxy.lib.le.ac.uk/login?url=http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=4769056>

159

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey.

<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>